| Title |
The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline
|
|---|---|
| Published in |
Ophthalmology and Therapy, August 2015
|
| DOI | 10.1007/s40123-015-0038-y |
| Pubmed ID | |
| Authors |
Laura A. Vickers, Preeya K. Gupta |
| Abstract |
Dry eye syndrome is both a primary disease and a secondary result of many pathological states of the eye. The symptoms range from mild to severe itching, burning, irritation, eye fatigue, and even vision loss that can lead to disability. Dry eye affects approximately 60 million people worldwide; as a result, medications to treat dry eye comprise approximately 15% of the ophthalmic pharmaceutical market. While doctors and patients eagerly await new treatments, pharmaceuticals in the pipeline are moving through the approval process with several promising drugs having completed phase 3 clinical testing. This review summarizes the findings of studies of the most promising, upcoming dry eye treatments in phase 2 and 3 clinical trials in the USA. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 24% |
| Other | 4 | 11% |
| Student > Master | 4 | 11% |
| Student > Ph. D. Student | 3 | 8% |
| Student > Postgraduate | 2 | 5% |
| Other | 5 | 13% |
| Unknown | 11 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 37% |
| Biochemistry, Genetics and Molecular Biology | 3 | 8% |
| Agricultural and Biological Sciences | 2 | 5% |
| Mathematics | 1 | 3% |
| Business, Management and Accounting | 1 | 3% |
| Other | 5 | 13% |
| Unknown | 12 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2023.
All research outputs
#3,125,355
of 24,535,155 outputs
Outputs from Ophthalmology and Therapy
#47
of 687 outputs
Outputs of similar age
#39,671
of 271,016 outputs
Outputs of similar age from Ophthalmology and Therapy
#1
of 4 outputs
Altmetric has tracked 24,535,155 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 687 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 271,016 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them